206 related articles for article (PubMed ID: 35843988)
1. Epigenetic restoration and activation of ERβ: an inspiring approach for treatment of triple-negative breast cancer.
Salahuddin A; Ghanem H; Omran GA; Helmy MW
Med Oncol; 2022 Jul; 39(10):150. PubMed ID: 35843988
[TBL] [Abstract][Full Text] [Related]
2. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
[TBL] [Abstract][Full Text] [Related]
3. Reactivation of estrogen receptor α by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor.
Stark K; Burger A; Wu J; Shelton P; Polin L; Li J
PLoS One; 2013; 8(9):e74525. PubMed ID: 24058584
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial strategy of epigenetic and hormonal therapies: A novel promising approach for treating advanced prostate cancer.
Motawi TK; Darwish HA; Diab I; Helmy MW; Noureldin MH
Life Sci; 2018 Apr; 198():71-78. PubMed ID: 29455003
[TBL] [Abstract][Full Text] [Related]
5. Influence of cellular ERalpha/ERbeta ratio on the ERalpha-agonist induced proliferation of human T47D breast cancer cells.
Sotoca AM; van den Berg H; Vervoort J; van der Saag P; Ström A; Gustafsson JA; Rietjens I; Murk AJ
Toxicol Sci; 2008 Oct; 105(2):303-11. PubMed ID: 18644836
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV
J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773
[TBL] [Abstract][Full Text] [Related]
7. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
Mishra AK; Abrahamsson A; Dabrosin C
Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells.
Hinsche O; Girgert R; Emons G; Gründker C
Int J Oncol; 2015 Feb; 46(2):878-84. PubMed ID: 25420519
[TBL] [Abstract][Full Text] [Related]
9. HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts.
de Cremoux P; Dalvai M; N'Doye O; Moutahir F; Rolland G; Chouchane-Mlik O; Assayag F; Lehmann-Che J; Kraus-Berthie L; Nicolas A; Lockhart BP; Marangoni E; de Thé H; Depil S; Bystricky K; Decaudin D
Breast Cancer Res Treat; 2015 Jan; 149(1):81-9. PubMed ID: 25503779
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting of Notch and Wnt/β-catenin pathways: Potential approach in triple-negative breast cancer treatment.
Nasser F; Moussa N; Helmy MW; Haroun M
Naunyn Schmiedebergs Arch Pharmacol; 2021 Mar; 394(3):481-490. PubMed ID: 33052427
[TBL] [Abstract][Full Text] [Related]
11. Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier.
Ma W; Sun J; Xu J; Luo Z; Diao D; Zhang Z; Oberly PJ; Minnigh MB; Xie W; Poloyac SM; Huang Y; Li S
Theranostics; 2020; 10(6):2463-2478. PubMed ID: 32194813
[TBL] [Abstract][Full Text] [Related]
12. Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro.
Schüler-Toprak S; Häring J; Inwald EC; Moehle C; Ortmann O; Treeck O
BMC Cancer; 2016 Dec; 16(1):951. PubMed ID: 28003019
[TBL] [Abstract][Full Text] [Related]
13. Roles of estrogen receptor alpha and beta in modulating urothelial cell proliferation.
Teng J; Wang ZY; Jarrard DF; Bjorling DE
Endocr Relat Cancer; 2008 Mar; 15(1):351-64. PubMed ID: 18310301
[TBL] [Abstract][Full Text] [Related]
14. Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function.
Song IS; Jeong YJ; Jeong SH; Kim JE; Han J; Kim TH; Jang SW
Cell Physiol Biochem; 2019; 52(3):468-485. PubMed ID: 30873822
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor-beta agonist diarylpropionitrile counteracts the estrogenic activity of estrogen receptor-alpha agonist propylpyrazole-triol in the mammary gland of ovariectomized Sprague Dawley rats.
Song X; Pan ZZ
J Steroid Biochem Mol Biol; 2012 May; 130(1-2):26-35. PubMed ID: 22266284
[TBL] [Abstract][Full Text] [Related]
18. Research resource: global identification of estrogen receptor β target genes in triple negative breast cancer cells.
Shanle EK; Zhao Z; Hawse J; Wisinski K; Keles S; Yuan M; Xu W
Mol Endocrinol; 2013 Oct; 27(10):1762-75. PubMed ID: 23979844
[TBL] [Abstract][Full Text] [Related]
19. Modulation of Estrogen α and Progesterone Receptors in Triple Negative Breast Cancer Cell Lines: The Effects of Vorinostat and Indole-3-Carbinol In Vitro.
Nouri Emamzadeh F; Word B; Cotton E; Hawkins A; Littlejohn K; Moore R; Miranda-Carbon G; Orish CN; Lyn-Cook B
Anticancer Res; 2020 Jul; 40(7):3669-3683. PubMed ID: 32620606
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
Su Y; Hopfinger NR; Nguyen TD; Pogash TJ; Santucci-Pereira J; Russo J
J Exp Clin Cancer Res; 2018 Dec; 37(1):314. PubMed ID: 30547810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
